The short answer
BPC-157 is a 15-residue peptide from a gastric juice protein at 1419.5 Da, with registered clinical trials including a recruiting Phase 2. TB-500 is a 7-residue fragment of thymosin beta-4's actin-binding motif at 889.0 Da, whose most-cited findings largely used the full protein.
Key facts
- BPC-157
- 15 residues, 1419.5 Da
- TB-500
- 7 residues, 889.0 Da
- BPC-157 origin
- Gastric juice protein sequence
- TB-500 origin
- Thymosin beta-4 residues 17-23
- BPC-157 mechanism
- Reported multi-pathway
- TB-500 mechanism
- Actin sequestration
- BPC-157 clinical
- Phase 2 recruiting (NCT07437547)
- TB-500 clinical
- No established programme
Different molecules entirely
They share nothing structurally. BPC-157 is fifteen residues, proline- and glycine-rich, derived from a gastric juice protein. TB-500 is seven residues, an internal motif of a 43-residue actin-binding protein with an acetylated N-terminus. Different sequences, different sizes, different parents.
Different mechanistic pictures
TB-500's mechanism is comparatively well defined: its parent is the principal G-actin sequestering protein in many cell types, and the fragment carries the motif associated with that. BPC-157's reported mechanism is multi-pathway and correspondingly less sharp (angiogenic signalling, growth-factor interactions and effects across several systems), without a single defining molecular action.
Research material referenced
BPC-157 5mg, third-party HPLC tested
The evidential difference that actually separates them
This is the most useful distinction and it is rarely made. BPC-157 has entered registered clinical development as PL-14736 for inflammatory bowel disease, with a Phase 1 study in 42 healthy volunteers and a randomised placebo-controlled Phase 2 recruiting now with 120 participants. TB-500 has no comparable programme. Meanwhile much of TB-500's most-cited literature used full-length thymosin beta-4 rather than the fragment sold under the name.
What they have in common
Both are preclinically characterised largely in rodent models. Both are associated with repair and healing language in commercial writing that outruns what the studies measured. Both are WADA-relevant. And both are supplied for laboratory research with no marketing authorisation anywhere.
On combining them
They appear together in commercial blends, and the rationale offered is mechanistic non-overlap. Whether combination has been studied as such is a separate question, addressed in the TB-500 category. The short answer is that a rationale is not a result, and the factorial design that would test it does not exist.
Quick reference
| BPC-157 | TB-500 | |
|---|---|---|
| Residues | 15 | 7 |
| Molecular weight | 1419.5 Da | 889.0 Da |
| Origin | Gastric juice protein | Thymosin β4, residues 17-23 |
| CAS | 137525-51-0 | None (parent: 77591-33-4) |
| PubChem CID | 9941957 | 62707662 |
| Mechanism | Multi-pathway, less defined | Actin sequestration |
| Registered trials | Phase 1 and Phase 2 | None established |
Frequently asked questions
Which has better evidence?
BPC-157, on the basis that it has entered registered clinical development including a currently recruiting placebo-controlled Phase 2. Neither has a reported clinical result.
Should they be used together?
That is a separate question from comparing them, covered in the TB-500 category. The combination rationale is mechanistic rather than tested.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- TrialClinicalTrials.gov: BPC 157 Phase 2 (NCT07437547)clinicaltrials.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · TB-500 (CID 62707662)pubchem.ncbi.nlm.nih.gov
- PubMedHannappel E, beta-Thymosins: Ann N Y Acad Sci 2007 (PMID 17468232)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- BPC-157 Structure and SequenceGEPPPGKPADDAGLV: fifteen residues, four prolines, three glycines, no cysteine or methionine and no aromatic residue. What that composition implies.
- The Proline Problem in BPC-157 SynthesisFour prolines, three consecutive, make solid-phase synthesis meaningfully harder. Why proline coupling is a recognised difficult step, and what it costs purity.
- BPC-157 Molecular Structure and Physical Properties1419.5 Da, net negatively charged, highly water-soluble, conformationally mixed. The physical consequences of a proline- and glycine-rich fifteen-mer.
- Pentadecapeptide: The Word and What It Tells YouPenta-deca-peptide is fifteen. Where BPC-157 sits on the spectrum from short peptide to protein, and why fifteen residues is a useful size.
- What Does BPC-157 Stand For?BPC is body protection compound; 157 is a series designation with no chemical meaning. Why the name is a claim and where it came from.